Investment Analysts’ Weekly Ratings Changes for Revolution Medicines (RVMD)

Revolution Medicines (NASDAQ: RVMD) recently received a number of ratings updates from brokerages and research firms:

• 3/3/2025 – Revolution Medicines had its price target raised by analysts at HC Wainwright from $72.00 to $73.00. They now have a “buy” rating on the stock.
• 2/27/2025 – Revolution Medicines had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $67.00 price target on the stock.
• 2/27/2025 – Revolution Medicines had its price target lowered by analysts at Stifel Nicolaus from $80.00 to $78.00. They now have a “buy” rating on the stock.
• 2/27/2025 – Revolution Medicines had its price target lowered by analysts at Needham & Company LLC from $60.00 to $59.00. They now have a “buy” rating on the stock.

Revolution Medicines Stock Up 0.7 %

NASDAQ RVMD traded up $0.27 on Wednesday, reaching $38.43. 103,741 shares of the stock traded hands, compared to its average volume of 1,343,038. The firm’s fifty day simple moving average is $40.86 and its 200 day simple moving average is $45.83. The company has a market cap of $7.14 billion, a price-to-earnings ratio of -10.70 and a beta of 1.46. Revolution Medicines, Inc. has a 12 month low of $29.55 and a 12 month high of $62.40.

Revolution Medicines (NASDAQ:RVMD) last released its quarterly earnings data on Wednesday, February 26th. The company reported ($1.12) earnings per share for the quarter, missing the consensus estimate of ($1.01) by ($0.11). As a group, equities research analysts forecast that Revolution Medicines, Inc. will post -3.49 EPS for the current fiscal year.

Institutional Trading of Revolution Medicines

Hedge funds have recently modified their holdings of the business. IFP Advisors Inc purchased a new stake in shares of Revolution Medicines in the fourth quarter valued at $34,000. Quarry LP purchased a new stake in shares of Revolution Medicines during the third quarter worth $82,000. Sterling Capital Management LLC raised its holdings in shares of Revolution Medicines by 588.7% during the fourth quarter. Sterling Capital Management LLC now owns 1,956 shares of the company’s stock worth $86,000 after acquiring an additional 1,672 shares in the last quarter. Farther Finance Advisors LLC raised its holdings in shares of Revolution Medicines by 368.3% during the fourth quarter. Farther Finance Advisors LLC now owns 2,051 shares of the company’s stock worth $90,000 after acquiring an additional 1,613 shares in the last quarter. Finally, Kapitalo Investimentos Ltda purchased a new stake in shares of Revolution Medicines during the fourth quarter worth $104,000. Hedge funds and other institutional investors own 94.34% of the company’s stock.

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.